# Inflammation-Induced CNS Glutamate Changes in Depression

> **NCT03004443** · PHASE4 · TERMINATED · sponsor: **Emory University** · enrollment: 22 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03004443
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-15
- **Primary completion:** 2019-11-27
- **Final completion:** 2019-11-27
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** The study was suspended in March 2020 due to the COVID-19 pandemic and ultimately was terminated as it is not safe to test a potent anti-inflammatory drug with ongoing surges of COVID-19.
- **Last updated:** 2023-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03004443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03004443, "Inflammation-Induced CNS Glutamate Changes in Depression". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03004443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*